A systematic review of peptide nucleic acids (PNAs) with antibacterial activities: efficacy, potential and challenges.
Peptide nucleic acid (PNA)
antibacterial drugs
antibiotic alternative
antisense oligonucleotide
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
05 Jan 2024
05 Jan 2024
Historique:
received:
12
09
2023
revised:
11
12
2023
accepted:
30
12
2023
medline:
8
1
2024
pubmed:
8
1
2024
entrez:
7
1
2024
Statut:
aheadofprint
Résumé
Peptide nucleic acids (PNAs) are synthetic molecules that are like DNA/RNA, but with different building blocks. They have been studied as potential antibiotics because they can specifically target and bind to mRNAs and disrupt the function of a targeted gene. This systematic review aims to provide an in-depth analysis of the current state of PNAs as antibacterial agents, define the characteristics of the effective PNA constructs, and address the gap in the PNA advancement to be clinically competent agents. Following the PRISMA model, we searched four electronic databases: Web of Science, PubMed, SciFinder and Scopus, and found 627 published articles between 1994 and 2023. After screening and a rigorous selection process using explicit inclusion and exclusion criteria, 65 scientific articles were selected, containing 656 minimum inhibitory concentration (MIC) data. The antibacterial activity of the PNAs was assessed against 20 bacterial species. The most studied Gram negative and Gram positive were Escherichia coli (n=266) and Staphylococcus aureus (n=53), respectively. Additionally, we revealed the effect of PNA design such as the construct length, binding location, and carrier agents on their antibacterial activities. Finally, we examined the effects of antibacterial test models to assess PNA's inhibitory effects, emphasizing gaps and prospects. This systematic review provides a comprehensive assessment of the potential of PNAs as antibacterial agents and offers valuable insights for researchers and clinicians seeking novel therapeutic strategies to combat antibiotic-resistant bacteria.
Identifiants
pubmed: 38185398
pii: S0924-8579(24)00001-3
doi: 10.1016/j.ijantimicag.2024.107083
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107083Informations de copyright
Copyright © 2024. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest There are no conflicts of interest to be declared.